Author's response to reviews

Title: Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England

Authors:

Dominic Thorrington (dominic.thorrington@phe.gov.uk)
Edwin van Leeuwen (edwin.vanleeuwen@phe.gov.uk)
Mary Ramsay (mary.ramsay@phe.gov.uk)
Richard Pebody (richard.pebody@phe.gov.uk)
Marc Baguelin (marc.baguelin@phe.gov.uk)

Version: 2 Date: 11 Aug 2017

Author’s response to reviews:

1.) Please include a list of abbreviations

This has been included in the relevant section of the manuscript

2.) As it is not in line with our in-house style, please incorporate the 'Research in context' section into the 'Discussion'

Much of this section is repetition of points already raised in the manuscript. As such, we propose a minor amendment to one paragraph in the Discussion to ensure that the right points are made without repetition.

Current version

Possible explanations and implications for clinicians and policymakers

Extending a QIIV programme to include clinical risk individuals of age under 65 years old in England is more likely to be cost-effective than extending further to also include all elderly individuals. However, the maximum incremental cost-per-dose of the quadrivalent vaccines is just £1.84.

Suggested new version

Possible explanations and implications for clinicians and policymakers
Extending a QIIV programme to include clinical risk individuals of age under 65 years old in England is more likely to be cost-effective than extending further to also include all elderly individuals. However, the maximum incremental cost-per-dose of the quadrivalent vaccines is just £1.84 meaning that the current policy of reimbursing GPs and Pharmacists for administering QIIV to clinical risk groups is likely to be cost-effective if the incremental reimbursement cost is less than this value.